Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes

Laura Panattoni (), Paul M. Brown, Braden Te Ao, Mark Webster and Patrick Gladding
Additional contact information
Laura Panattoni: University of Auckland
Paul M. Brown: University of Auckland
Braden Te Ao: University of Auckland
Mark Webster: University of Auckland
Patrick Gladding: University of Auckland

PharmacoEconomics, 2020, vol. 38, issue 3, No 8, 315-315

Abstract: Unfortunately, the article’s Supplementary File Link is not working and the ESM material.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-020-00885-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:38:y:2020:i:3:d:10.1007_s40273-020-00885-8

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-020-00885-8

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().